Financial Data and Key Metrics Changes - The company reported Q1 revenue of €8.6 billion, growing 8.4% reported and 4.8% organic, in line with guidance [38] - Adjusted EPS was €1.26, exceeding the midpoint of guidance by €0.03 [42] - Adjusted gross margin was 65.1%, down 80 basis points year over year, but stable compared to Q4 [38] Business Line Data and Key Metrics Changes - Cardiovascular grew 7% this quarter, driven by nearly 50% growth in Cardiac Ablation Solutions [21][22] - Neuroscience grew 3%, with high single-digit growth in neurosurgery and neuromodulation [11][28] - MedSurg grew 2%, with high single-digit growth in Advanced Energy [31] - Diabetes grew 8%, with 11% growth in international markets [34] Market Data and Key Metrics Changes - The U.S. market showed slower growth in certain segments, particularly in diabetes and pelvic health, while international markets performed better [60] - The company expects to ramp up procedures for the SIMPLICITY system following CMS's proposed national coverage decision [25][27] Company Strategy and Development Direction - The company is focused on accelerating growth through innovation and strategic investments in high-growth areas like CAS and Ardian [19][20] - A planned separation of the diabetes business is expected to enhance focus on core businesses and improve revenue and earnings growth [19][37] - New board committees have been established to enhance focus on growth and operational efficiency [48][49] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in accelerating growth in the second half of fiscal 2026, driven by strong demand and new product launches [7][19] - The company anticipates significant revenue growth from its PFA portfolio and other upcoming product launches [13][14] - Management highlighted the importance of maintaining pricing discipline and improving operational efficiencies to support growth [38][45] Other Important Information - The company is increasing investments in R&D, with a 7.7% increase in adjusted R&D spending [40] - The anticipated impact of tariffs has been adjusted, with expectations now at approximately €185 million for fiscal 2026 [44] Q&A Session All Questions and Answers Question: Update on CAS growth and its impact on U.S. growth - Management confirmed that CAS growth is accelerating and will positively impact U.S. growth, despite some segments showing slower growth [56][58] Question: Impact of new board committees on governance and operations - The new committees will provide focused oversight on growth and operational performance, with increased interaction with management expected to drive improvements [68][70] Question: Commitment to CAS annual sales target - Management reaffirmed the commitment to achieving $2 billion in annual CAS sales, indicating strong confidence in the growth trajectory [76][78] Question: Discussion on capital allocation and potential changes - Management indicated that the new board members and committees will facilitate discussions on capital allocation and value creation strategies [81][89] Question: Overall portfolio growth expectations - Management stated that while significant growth opportunities exist, they will not neglect the rest of the business and expect to see incremental growth from various segments [99][100]

Financial Data and Key Metrics Changes - Fortive reported adjusted earnings per share of $0.85, which is in line with expectations, reflecting a 2% year-over-year growth [5][14] - Core revenue declined by 2% year-over-year, slightly below expectations, with total revenue down 3% due to foreign exchange headwinds [13][14] - Adjusted operating profit was $373 million, with adjusted operating margin expansion of 20 basis points [14] - Adjusted free cash flow was better than expected at $222 million, with a 7% increase in six-month growth [14][27] Business Line Data and Key Metrics Changes - Intelligent Operating Solutions (IOS) segment grew core revenues by 2%, while Advanced Healthcare Solutions (AHS) grew by 2.5% [16][18] - Precision Technologies (PT) segment experienced an 8.4% core revenue decline, driven by lower orders in Test and Measurement and shipment delays in Sensors and Safety Systems [13][20] - IOS segment adjusted operating margins expanded by 150 basis points, while AHS saw a 70 basis point contraction in adjusted operating margins [17][19] Market Data and Key Metrics Changes - North America showed stable industrial demand, while Europe and China faced a more challenging macro environment [16] - The company expects China to be down high single digits for the year, reflecting increased challenges [126] - Overall, North America is anticipated to remain the strongest market for Fortive [125] Company Strategy and Development Direction - Fortive is focusing on enhancing supply chain resilience, having reduced exposure to imports from China by 70% since 2018 [7][23] - The company is targeting the completion of its separation by the end of the second quarter, which is expected to unlock shareholder value [30][32] - Fortive aims to increase its recurring revenue mix from approximately 40% to roughly 50% post-separation [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a more dynamic macro environment and moderating demand in PT, with expectations for a modest improvement in the segment [7][28] - The company is implementing countermeasures to mitigate tariff impacts, estimating a gross tariff impact of $190 million to $220 million [24][27] - Management remains confident in the ability to navigate current challenges and deliver best-in-class net working capital performance [27][30] Other Important Information - The company announced the appointment of a new CFO, Mark Okerstrom, who is expected to drive additional shareholder value [8][10] - Fortive's strategic approach includes pricing adjustments and optimizing sourcing and logistics to mitigate tariff impacts [25][26] Q&A Session Summary Question: Clarification on localizing production - Management indicated that localizing production involves accelerating existing plans rather than building new capacity in the U.S. [41][42] Question: Insights on Test and Measurement decline - The decline was attributed to customers delaying orders due to increased policy and macro uncertainty, with expectations for recovery pushed to 2026 [44][46] Question: Volatility in Test and Measurement industry - The volatility is linked to the sector's exposure to R&D investments, which customers can delay amid economic uncertainty [53][55] Question: Clarification on tariff impacts - Management clarified that the estimated tariff impact for 2025 is around $200 million, with plans to offset about 80% of it [82][90] Question: Expectations for North America and Western Europe - North America is expected to perform well, while China is anticipated to face challenges, with a projected decline in revenue [125][126]

Financial Data and Key Metrics Changes - Honeywell exceeded the high end of its guidance on all metrics in the first quarter, with organic sales growth of 4% year over year [4][18] - Adjusted earnings per share (EPS) was $2.51, up 7% year over year, while earnings per share remained flat at $2.22 [20][21] - First quarter cash flow exceeded $300 million, over $100 million above the prior year, driven by better adjusted earnings [20] Business Line Data and Key Metrics Changes - Aerospace Technologies saw a 9% organic sales increase, with commercial aftermarket sales growing 15% due to robust demand [22] - Industrial Automation sales declined 2% organically, primarily due to lower demand in personal protective equipment [23] - Building Automation grew 8% organically, driven by strong demand in both Building Solutions and Building Products [25] - Energy and Sustainability Solutions sales declined 2% organically, while Advanced Materials sales decreased by 4% [26] Market Data and Key Metrics Changes - Orders for the first quarter were $10.6 billion, up 3% year over year, with a record organic backlog growth of 8% [20] - Aerospace industry demand continues to outpace supply, supporting orders growth of 9% and a book-to-bill ratio of 1.1 [22] Company Strategy and Development Direction - Honeywell is focused on separating into three standalone public companies to unlock significant value and position each for long-term growth [9][10] - The company is actively pursuing acquisitions, with the recent acquisition of Sundyne being part of its portfolio transformation strategy [12][14] - Honeywell's local for local strategy aims to mitigate the impact of tariffs and geopolitical tensions by serving local markets [15][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged increasing economic uncertainty and shifting global trade patterns but remains confident in achieving its 2025 outlook [4][5] - The company is maintaining its full-year organic growth guidance while raising its adjusted EPS guidance [5][29] - Management emphasized the importance of ongoing mitigation efforts and a strong operational framework to navigate current challenges [16][28] Other Important Information - Honeywell has repurchased approximately $3 billion of its shares in 2025, with plans to continue opportunistic buybacks [11][33] - The company expects free cash flow for the year to be between $5.4 billion and $5.8 billion, down 2% to up 5% excluding the Bombardier impact [32] Q&A Session Summary Question: Details on tariffs and offset strategies - Management confirmed that the estimated tariff impact is approximately $500 million, with strategies including pricing adjustments and productivity measures to mitigate this impact [47][48] Question: Volume assumptions and contingency - Management indicated a conservative approach to guidance, assuming a volume decline of 1% to 2% and a price increase of about 3% [60] Question: Impact of tariffs by segment - The largest tariff exposure is in Industrial Automation and Aerospace, with Building Automation being largely protected due to its local strategy [87] Question: Aerospace aftermarket performance - The commercial aftermarket grew 15%, driven by strong demand and a positive backlog, with no significant changes in pricing expectations [108][109] Question: Supply chain exposure to China - Management noted that while there is tariff pressure, they do not foresee a shortage of parts, focusing instead on demand destruction due to tariffs [102][105]